At the IGTP TODAY

News

- Campus Can Ruti, Research

New study finds a promising combined therapy for multiple sclerosis

Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.

- Projects, Research

Keeping a longer overnight fast and eating an early breakfast may be associated with a lower body mass index

To keep weight in check, it is not only important to consider what we eat, but also the times at which we eat. According to a study published in the International Journal of Behavioral Nutrition and Physical Activity, there are two specific habits that are associated with a lower body mass index (BMI) in the long term: keeping a longer overnight fast and eating breakfast early. This research was led by ISGlobal and was carried out in collaboration with the GCAT cohort from IGTP.

- Campus Can Ruti, Research

The Research Institute of the Germans Trias i Pujol Hospital demonstrates how personalised medicine helps to control the effects of acromegaly earlier

IGTP leading the first study in the world to prove that personalised therapies are more effective than classic drugs indicated for the treatment of this rare hormonal disease. It is based on response biomarkers that, depending on what they indicate, allow the best possible treatment to be assigned earlier. In addition to very noticeable facial and skeletal deformities, acromegaly causes severe alterations in other parts of the body. Published in The Journal of Clinical Endocrinology & Metabolism.

- Research

A new biomarker shows potential to evaluate treatment response for metastatic colorectal cancer

A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d’Oncologia (ICO) analysed peripheral blood samples from patients with metastatic colorectal cancer and identified a potential biomarker indicating the effectiveness of oxaliplatin-based treatment. The research has been published in the journal Biomedicine & Pharmacotherapy.

- Research

A new study reveals the underuse of a key drug in patients with treatment-resistant schizophrenia

The Psychiatry and Mental Health Research Group at IGTP, together with the ETEP (Study and Treatment of Psychotic Episodes) group at Hospital del Mar, has published a new study analysing the prescription patterns of clozapine in patients with a first psychotic episode. This study highlights the importance of broader and earlier implementation of this treatment to improve the quality of life for patients.

IGTP and DevsHealth join forces to develop new antibiotics against hospital-acquired infections by multi-resistant Staphylococcus aureus

DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.

- Projects, Research

Decoding depression amidst COVID-19: a comprehensive analysis of genetic and environmental stressors by GCAT

As a strategic initiative under IGTP, GCAT (Genomes for Life) continues to make substantial contributions to public health knowledge. The latest GCAT study, conducted through the COVICAT initiative, signed by Ximena Goldberg and Rafael de Cid, sheds light on the complex interplay between genetic predispositions and environmental stressors in determining depression risk, especially during the COVID-19 lockdown. Published in Scientific Reports.